Signals, Powered By EquityPandit
Natco Pharma has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets that are used in treatment of chronic hepatitis C, in India.
Natco Pharma has said in a BSE filing that the company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name ‘Velpanat’.
This product of the company is generic version of Gilead Sciences Inc’s Epclusa tablets.
Natco has said that Epclusa is used in treating adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis.
